Treatment of canine osteoarthritis using adipose purified microlobules (APM), in collaboration with the National Veterinary School of Nantes (Oniris): This study showed positive and promising results with a significant improvement of the pain (+47%), lameness (+73%), vertical and impulse force (+17% for each force) after treatment.
Treatment of human knee osteoarthritis using adipose purified microlobules (APM): The end of patients inclusion and surgical procedures confirmed the safety of the treatment.
Stemcis registered a new patent for the obtention of Adipose Tissue Purified Cells (ATPC) by mechanical dissociation. This innovative method helps extracting ATPC within a few minutes, compared to conventional enzymatic systems lasting 1 to 3 hours generally. Preclinical studies are currently conducted on rats to assess the efficacy of our device for the treatment of erectile dysfunctions.
2018 Medtech Boston Program
The trainings delivered during the week, as well as the quality of the interactions with several executives already present in the US allowed Stemcis to refine its development and market access strategies in this major market. Stemcis is considering the first product sales in early 2019.
23-27 April 2018
Stemcis participates in the 2018 Medtech Boston program, April 23-27, for an immersion in the heart of the North American health ecosystem.
Throughout the week, workshops dedicated to the reimbursement system and the organization of the American health system are planned, as well as mentoring and pitching sessions at two events dedicated to health technologies. Thanks to this program, Stemcis will benefit from a better visibility on the North American market that it wants to conquer this year.